Skip to main content

Dionex to Buy ESA Biosciences' HPLC Assets

NEW YORK (GenomeWeb News) – Dionex, a maker of liquid chromatography analysis systems, said today that it plans to buy ESA Biosciences' life sciences assets from ESA's parent company, Magellan Biosciences, including ESA's HPLC systems and clinical assays, as well as lab services.

The asset purchase agreement will give Sunnyvale, Calif.-based Dionex three lines of HPLC detectors. These products include the Corona Universal Charged Aerosol Detectors, which Dionex will sell with its own HPLC equipment or directly on third party systems.

The other two product lines, the CoulArray and Coulocheme electrochemical detectors are targeted at clinical, metabolomics, and neuroscience applications.

Dionex President and CEO Frank Witney said in a statement that the electrochemical detectors "will expand our HPLC offering and help us serve our customer demands by providing a broader and stronger spectrum of sensitive and robust HPLC and UHPLC application solutions."

Financial terms of the agreement were not released.

Filed under

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.